Announcement of Availability for CDX-1140

May 26, 2023

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using CDX-1140, a fully human IgG2 agonist anti-CD40 monoclonal antibody, which is being developed by CTEP as an anticancer agent in collaboration with Celldex Therapeutics. CTEP will also consider requests to supply CDX-1140 for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

If you are a DFHCC Investigator interested in submitting an LOI using CDX-1140 through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)

Questions may be addressed to Dr. Cheryl Pickett (cheryl.pickett@nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)

For more information please see the related documents below